Patrick Griffin

e.l.f. Beauty, a titan of viral cosmetics, is entering the haircare chat. This is more than a new product; it's a test of its disruptive model.

A new white-label infrastructure from PsyMetrics allows independent HR advisors to rebrand assessment tech, aiming to end "client leakage" to large vendors.

As the powersports industry faces a crippling technician shortage, Yamaha stands alone, betting on youth education to secure its future and its dealer network.

A silent productivity drain is costing businesses dearly. Over half the workforce aged 40-60 is managing elder care, and the financial and career toll is immense.

Sumitomo Pharma's new data reveals a potent combination therapy for myelofibrosis and decodes resistance in leukemia, shaking up a competitive oncology landscape.

As nurses and for-profit homes enter bitter arbitration, the standoff exposes a critical flaw in long-term care: a business model at odds with its mission.

Apollo Art Auctions' latest sale, featuring a mysterious 'Prince Collection,' puts the spotlight on the modern antiquities market's high-stakes game of trust.

A new report reveals vulnerability growth is outpacing enterprise defenses, shrinking response times to hours. This isn't just an IT issue—it's a boardroom crisis.

A new collaboration between TAP and Truist Foundation aims to bolster 500 small businesses by focusing on financial health, a critical but often overlooked metric.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

A Texas university is building a city-within-a-city. Is this a bold new model for institutional survival or a high-stakes gamble on real estate?

As Europe grapples with energy costs and net-zero goals, Cortec's Croatian subsidiaries offer a powerful model for a circular, self-powered supply chain.

Logitech's new Mobi Fold isn't just a clever gadget. It's a strategic assault on the trackpad, aiming to close the productivity gap for hybrid professionals.

A new study by SciBase and Castle Biosciences is testing technology to predict atopic dermatitis flares, promising a shift from reactive care to patient control.

ERock hits the NYSE, selling investors on a solution to the AI energy crisis. But with steep losses and regulatory hurdles, its future is far from guaranteed.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

Asante and WesternU launch a strategic partnership to embed medical students in the Rogue Valley, tackling physician shortages with a 'grow your own' model.

As Dubai's property market matures, IPS 2026 emerges as more than a showcase, creating a vital ecosystem where global capital meets next-gen urban innovation.

A partial settlement for California American Water's rates offers a preview of a national dilemma: how to pay for vital upgrades without overburdening consumers.

As AI costs soar and security risks mount, a new open-source microhypervisor aims to rebuild trust from the silicon up. Is this the architectural shift we need?